---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-25-000112"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:52.331543+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025

## Summary
- Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.
- Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.
- Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.
- VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.
- Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply.

## SEC filing metadata
- accession: 0001649094-25-000112
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/0001649094-25-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-25-000112
- JSON: https://secwatch.observer/filing/0001649094-25-000112.json
- Plain text: https://secwatch.observer/filing/0001649094-25-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.